Ultrasensitive MRD Detection as a Biomarker for Patient Selection, Drug Efficacy, and Recurrence
Time: 9:30 am
day: Conference Day 2
Details:
- NeXT Personal is an analytically validated, tumor-informed liquid biopsy assay with consistent ultrasensitive 1-3 PPM detection
- Ultrasensitive MRD detection at baseline, landmark, and longitudinal timepoints across multiple cancer indications demonstrates an ability to accurately identify responders quickly, as well as advantages over commonly used endpoint measurements
- NeXT Personal can accelerate decisions in drug development through trial enrichment, dose selection, efficacy evaluation, recurrence monitoring, and surrogate endpoint analysis
